Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $50
10x Genomics -1.50%
10x Genomics TXG | 15.14 | -1.50% |
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:
TXG) with a Buy and lowers the price target from $65 to $50.